Manuel Vadillo-Buenfil

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.

György B. Halmos, Andrew V. Schally, J. Pinski et al. · Proceedings of the National Academy of Sciences · 1996 · 96 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II

A. Jungwirth, J. Pinski, Georg Galvan et al. · European Journal of Cancer · 1997 · 96 citations · Full text

Medicine, Oncology, Pharmacology +12

Responses to the antagonistic analog of LH‐RH (SB‐75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

David González-Bárcena, Manuel Vadillo-Buenfil, F. Gómez-orta et al. · The Prostate · 1994 · 90 citations

Medicine, Pharmacology, Pharmacotherapy +14

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone

A. Jungwirth, J. Pinski, György B. Halmos et al. · British Journal of Cancer · 1997 · 86 citations · Full text

Medicine, Oncology, Pharmacology +14

Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.

J. Pinski, Najib Lamharzi, György B. Halmos et al. · Endocrinology · 1996 · 74 citations · Full text

Medicine, Endocrinology, Pharmacology +17